Shares of Amarin Corp’s (AMRN.O) rose as much as 9 percent to their year high on Thursday morning, after the Irish company accidently put up a website showing that its experimental heart drug had been approved by U.S. drug regulators. The drug, which aims to cut fat content in the blood, is still under marketing review by the U.S. Food and Drug Administration. A decision is expected on July 26. Amarin said in a regulatory filing that the information was inadvertently published through a draft website that is under design by third parties on behalf of Amarin.
